cbdMD, Inc. Earnings Per Share Disclosure
NOTE 14 – LOSS PER SHARE
The following table sets forth the computation of basic and diluted loss per share for the following periods:
| Year Ended | ||||||||
| September 30, | September 30, | |||||||
| 2025 | 2024 | |||||||
| Basic: | ||||||||
| Net loss | $ | (2,040,902 | ) | $ | (3,700,126 | ) | ||
| Preferred dividends paid or accrued | 2,334,501 | 4,004,001 | ||||||
| Net income loss attributable to cbdMD Inc. common shareholders | (4,375,403 | ) | (7,704,127 | ) | ||||
| Shares used in computing basic earnings per share | 4,022,629 | 539,069 | ||||||
| Shares used in computing diluted earnings per share | 4,022,629 | 539,069 | ||||||
| Earnings per share Basic: | - | |||||||
| Basic earnings per share | (1.09 | ) | (14.29 | ) | ||||
| Earnings per share Diluted: | ||||||||
| Diluted earnings per share | (1.09 | ) | (14.29 | ) | ||||
At the year ended September 30, 2025, 100,993 potential shares underlying options, unvested RSUs and warrants as well as 1.7 million shares issuable upon conversion of our Series B Preferred stock which are excluded from the shares used to calculate diluted loss per share as their inclusion would reduce net loss per share.
Want the next cbdMD, Inc. earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment cbdMD, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Dec 19, 2025 | Showing above |
| 2024 | Dec 18, 2024 | |
| 2023 | Dec 22, 2023 | |
| 2022 | Dec 15, 2022 | |
| 2020 | Dec 22, 2020 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.